Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
5.89
-0.04 (-0.59%)
At close: Dec 5, 2025, 4:00 PM EST
5.77
-0.12 (-1.95%)
After-hours: Dec 5, 2025, 4:10 PM EST
Kalaris Therapeutics Employees
Kalaris Therapeutics had 14 employees as of December 31, 2024.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,961,857
Market Cap
110.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KLRS News
- 12 days ago - Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Newsfile Corp
- 24 days ago - Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 weeks ago - Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer - GlobeNewsWire
- 5 weeks ago - Kalaris to Present at Stifel 2025 Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration - GlobeNewsWire
- 2 months ago - Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration - GlobeNewsWire
- 4 months ago - Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference - GlobeNewsWire